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Abstract: The objective of our study was to assess procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations in endstage renal disease (ESRD) patients undergoing haemodialysis sessions and the effect of intermittent haemodialysis on PCT levels.
We measured plasma PCT and CRP levels in 43 ESRD patients without evidence of systemic infection at the beginning of
haemodialysis and 4 hours later. Control group consisted of 40 volunteers with no complaints. Venous blood samples were collected
from the patient before and after hemodialysis and the control groups. PCT was assayed by immunoluminometry. The mean plasma
concentration of PCT (2.13 ± 0.7 ng/mL) and CRP (14.3 ± 2.9 mg/L) was elevated prior to the start of the patients hemodialysis
compared to healthy controls (PCT; 0.18 ± 0.03 ng/mL, CRP; 4.5 ± 2.2 mg/L) (P < 0.0001). After 4 h of haemodialysis, the levels
of PCT decreased significantly (P > 0.05). In addition, a weak correlation between PCT and CRP before dialysis was established. It
was found that PCT levels significantly increased in haemodialysis patients without signs of infection. This confirms the presence of
a chronic systemic inflammatory state in these patients. Although haemodialysis was associated with a significant decrease of serum
PCT, haemodialysis had no significant effect on CRP levels.
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Introduction
Systemic bacterial infections are a major clinical
problem in patients with end-stage renal disease (ESRD)
(1). The conventional laboratory variables such as white
blood cell count and erythrocyte sedimentation rate (ESR)
levels are often affected by the uremia or by the
haemodialysis process (2). A specific marker of bacterial
infection in renal patients should distinguish infection
from noninfectious inflammatory disorders.
Procalcitonin (PCT), the main precursor of calcitonin
hormone, is a polypeptide with 116 aminoacids. For the
first time in 1993, it was found to increase significantly
in serum in serious bacterial infections such as sepsis.
Later many researchers observed that PCT levels increase
in patients with trauma, burns and neutropenia as well as
infections such as meningitis, pneumonia (3,4). The
researches indicate that PCT can be an indicator of
immune activation and used in the future as a mediator to

monitor the continuity of this activation. However, it is
emphasized that in order for it to be accepted as a
potential tool for diagnosis and monitoring, studies must
be performed comparing with other values of the
inflammatory response in various groups of patients (35). C reactive protein (CRP) is an acute phase reactant
that increases in inflammatory responses and is
frequently used for follow-up (6,7).
In patients on haemodialysis, inflammation is
stimulated by acute-phase responses triggered by various
pathophysiological mechanisms such as exposure to
bacteria, endotoxins or viruses, and immunological
phenomenon that occur because of the biocompatibility of
the dialysis procedure, or metabolic and immunological
disorders due to chronic renal failure per se (8). Although
PCT has been described as a new marker of
inflammation, it has been extensively studied in dialysis
patients. As some studies have reported, CRP and PCT
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during haemodialysis has not been fully clarified. The aim
of the study was to assess PCT and CRP plasma
concentrations in ESRD patients undergoing
haemodialysis session and the effect of intermittent
haemodialysis on PCT levels.

Materials and Methods
The study involved 43 consecutive patients without
evidence of systemic infection between 19 and 68 years
age having chronic kidney disease and undergoing
haemodialysis treatment in Firat University, Firat Medical
Center. The control group included 40 volunteers, 20
male and 20 female, whose ages ranged between 18 and
60 (46.6 ± 14.8). The cases in the control group had
CRP within normal limits and did not have any
complaints. Table 1 shows the features of the patients
included in the study, the method and period of
haemodialysis treatment. None were treated with
corticosteroid and erythropoietin. There was no clinical
evidence of infection or major surgical procedures in the
three weeks preceding the study and none of these
patients had any immunologic or thromboembolic
disorder or malignancy.
Haemodialysis treatment was performed for 4 hours
3 times a week using bicarbonate-buffered dialysate. In
haemodialysis, polysulphone dialyser (Hemoflow F6,
Fresenius, Germany), and low molecular weight heparin
Table 1. Clinical characteristics of the 43 patients.
Sex ratio
Age(years)
Time on dialysis (year)
Hemoglobin levels (g/dl)
Urea reduction rate (%)
Kt/V (unit)

18M / 25F
47.02+ 14.7
3.76 + 0.3

The average age of patients in the study was 47 years
and 58.1% were women. The mean urea reduction ratio
was 68 ± 5%, mean Kt/V urea (Urea clearance x time/the
volume of distribution of urea) value 1.64 ± 0.32, mean
serum albumin concentration was 3.98 ± 0.47, and
protein catabolism rate (PCR) 1.6 ± 0.2. The mean
hemoglobin value of the patients was 9.3 ± 0.4g/dL. It was
found that the most frequent cause of the chronic kidney
disease was diabetes mellitus. From the 43 patients
undergoing haemodialysis, venous blood samples were
taken before and after the 4 hours of dialysis. Venous
blood samples were also taken from those in the control
group; blood samples were taken immediately centrifuged
0
and kept at -80 C until the day of research. Procalcitonin
levels were determined by immunoluminometric assay
using BRAHMS kits (Brahms Diagnostica, Berlin,
Germany). CRP levels were measured by the
immunonephelometric assay using Dade Behring kits.
Statistical analysis
Statistical evaluation was made in Windows 98, using
SPSS software and Student T test and Wilcoxon tests for
nonparametric data. For analysis of correlation between
the values, Pearson correlation analyses were used. Data
were expressed as mean ± SD. Differences at the level of
P < 0.05 were considered statistically significant.

9.3 + 0.4
68 ± 5
1.64 ± 0.32

Primary renal diseases
Diabetes Mellitus

11 (% 25.6)

Glomerular disease

11 (% 25.6)

Hypertensive nephrosclerosis

4 (% 9.3)

Urolithiasis

4 (% 9.3)

Polycystic kidney disease

3 (% 6.9)

Amyloidosis

2 (% 4.7)

Vesicoureteral reflux

1 (% 2.3)

Unknown etiology

7 (%16.3)
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for anticoagulation (Fragmin 2000-5000 Ü) were used.
Blood flow rate was in the range of 200-300 mL/min;
ultrafiltration rate was between 300-1000 mL/hour. The
water treatment system consisted of simple reverse
osmosis. All dialysis generators were disinfected after
each dialysis procedure. Regular microbiological tests
showed no bacterial growth in any samples of the
bicarbonate-buffered dialysate. Vascular access was via an
arteriovenous fistula.

Results
In haemodialysis patients, mean PCT concentrations
showed a mean of 2.13 ± 0.7 ng/mL and in the control
group 0.18 ± 0.03 ng/mL (P < 0.0001, Table 2). The
PCT levels were above 0.5 ng/mL in 30 patients (69.7%)
at baseline versus 24 patients (55.8%) at the end of
haemodialysis (P > 0.05). On average, the PCT levels
decreased from 2.13 ± 0.7 ng/mL at baseline to 1.18 ±
0.3.ng/mL at the end of haemodialysis (P < 0.05). There
was no difference in urea reduction ratio or Kt/V between
patients with low or high PCT levels.
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Table 2. Pre- and post-haemodialysis PCT and CRP values of patients.
Control group

Pre-haemodialysis

Post-haemodialysis

PCT (ng/ml)

0.18 + 0.03

2.13 + 0.7*

1.18 + 0.3**

CRP (mg/l)

4.50 + 2.24

14.3 + 2.9***

13.4 + 3.18***

* P < 0.0001, vs. control
** P < 0.05, vs. pre-haemodialysis
*** P < 0.05, vs. control

Serum concentration of CRP was 14.3 ± 2.9 mg/L in
haemodialysis patients.. In the control group, CRP value
was 4.5 ± 2.2 mg/L (P < 0.05). There was no significant
difference in CRP plasma concentration with
haemodialysis. In comparison with pre-haemodialysis
PCT, it was found that PCT levels correlated only weakly
with CRP levels (r = 0.32, p = 0.02). No correlation was
found between post-haemodialysis PCT and CRP levels (r
= 0.07, p = 0.6, Table 2).

Discussion
High level of serum or plasma PCT is an indicator of
the magnitude of inflammation and the immune response
given by the scurf. PCT is at very high levels in sepsis and
serious infections, at medium levels in bacterial infections
of organs, at low levels in some parasitic and fungal
infections, and at normal levels in viral infections and
small-scale surgical operations. Normally the reference
value of PCT in the serum is below 0.5ng/ml (5). Sitter at
al suggested that PCT proved superior to other markers
of infection and might be a useful diagnostic marker in
renal patients with bacterial infection (9). The aim of the
present study was to evaluate PCT and CRP
concentrations in haemodialysis patients without signs of
infection. We demonstrated that PCT is high in
haemodialysis patients, and is decreased moderately after
haemodialysis session, and that PCT and CRP
concentrations are weakly correlated before
haemodialysis. Level C et al. found a relationship between
PCT and other inflammatory parameters such as CRP or
IL-6 (10). Although PCT is not produced by circulating
blood cells, its synthesis is closely dependent on IL-6 and
TNF α. Thus the presence of an elevated plasma PCT
levels in prehaemodialysis indicates that uremia per se
and not the dialysis process is the principle cause of
increased plasma PCT either directly or possibly as a
consequence of IL-6 and TNF α release (11).

In our study, PCT levels were decreased after
haemodialysis. The cause of this may be PCT clearance by
dialysis, because of its low molecular weight (12).
Nishikura et al. emphasized that PCT was first absorbed
by the filter membrane and then subjected to an
ultradiafilter, the PCT clearance seems to become
constant at 2.3 to 3.4 mL/min during a 5 h to 24 h
haemodiafiltration session (13). In one study, it was
demonstrated that high PCT levels were decreased by
high-flux membranes, but not low-flux membranes (14).
In fact increases in PCT levels by cytokine activation
during the course of haemodialysis would be expected.
However, Dandona et al. have shown that an initial
release of PCT in serum can be detected at the earliest 46 h after stimulation of endotoxin(15). Therefore, it may
be unlikely to observe an increase of PCT levels during
haemodialysis. This decrease in serum PCT may reduce
the sensitivity of PCT (11). We suggested that, in
haemodialysis patients, PCT plasma concentrations may
be altered independently of the presence, nature or
activity of infection.
In patients undergoing chronic haemodialysis the
immunoturbidimetry method revealed plasma CRP levels
of 24 ± 4.2 mg/mL and in the control group it was 1.7 ±
0.67 mg/mL (P < 0.001) (7). The high level of CRP in
inflammatory cases such as bacterial infection, trauma,
collagen tissue disease is non-specific and even if the
inflammation is removed the high level remains for some
time. However, the in vivo PCT half time is defined to be
about 25-30 hours. Dropping of high PCT levels is an
indicator of recovery. If it remains high or decreases very
slowly, there is no recovery (16, 17). Numerous studies
have reported a strong association between
inflammation, nutritional status, and mortality in dialysis
patients (2, 18). In addition, PCT could be considered as
an acute phase protein associated with the early phase of
inflammatory processes before the occurrence of
impaired nutritional status. In a research, 16 (44%) of
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the 36 chronic haemodialysis patients had serum PCT
levels of above 0.5 ng/ml whereas at post-dialysis, this
figure decreased to nine (25%) at the 240th minute. The
average pre-haemodialysis PCT level was 0.58 ± 0.35
ng/mL but it decreased to 0.44 ± 0.32 ng/mL in the postdialysis period. On the other hand, the CRP level, which
was 0.57 ± 0.44 mg/mL before haemodialysis, increased
to 0.70 ± 0.51 mg/mL after the treatment (17).
In our research, the high levels of PCT observed at
pre-dialysis in the chronic haemodialysis patients makes
us suspect the existence of a slight inflammation that is
not totally obvious and identifiable, and has a chronic
character. The determined CRP levels also support this
idea. CRP reference values are nephelometrically 0-5
mg/L. The CRP value we found is about twice the normal
value. Lock of significant difference in the CRP levels after
haemodialysis indicated that CRP was not eliminated with
haemodialysis, and haemodialysis had no significant effect

on CRP levels. CRP may be a useful marker of infection
in these patients.
In conclusion, it was observed that PCT levels
increased in patients on chronic haemodialysis. We
conclude that PCT is a possible marker of chronic
systemic inflammatory state in these patients, while CRP
is a valid marker of chronic inflammation. Although
haemodialysis was associated with a significant decrease
of serum PCT, haemodialysis had no significant effect on
CRP levels.
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